Stifel Nicolaus Raises AtriCure (NASDAQ:ATRC) Price Target to $48.00

AtriCure (NASDAQ:ATRC - Free Report) had its price objective increased by Stifel Nicolaus from $36.00 to $48.00 in a report issued on Thursday,Benzinga reports. They currently have a buy rating on the medical device company's stock.

A number of other equities research analysts have also recently issued reports on ATRC. Canaccord Genuity Group upped their price objective on shares of AtriCure from $61.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday. JMP Securities reiterated a "market outperform" rating and set a $60.00 price target on shares of AtriCure in a research note on Monday, February 10th. Oppenheimer upped their price target on AtriCure from $32.00 to $36.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Needham & Company LLC reiterated a "buy" rating and set a $51.00 price target on shares of AtriCure in a research note on Thursday. Finally, JPMorgan Chase & Co. upped their target price on AtriCure from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $51.56.

AtriCure Stock Up 3.4 %

Shares of NASDAQ ATRC traded up $1.35 during trading hours on Thursday, hitting $40.94. The stock had a trading volume of 577,628 shares, compared to its average volume of 590,066. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. The company has a market capitalization of $2.00 billion, a P/E ratio of -49.33 and a beta of 1.46. AtriCure has a 52 week low of $18.94 and a 52 week high of $43.11. The firm's 50-day moving average price is $35.76 and its two-hundred day moving average price is $31.50.

Institutional Investors Weigh In On AtriCure

Several hedge funds have recently modified their holdings of ATRC. Hood River Capital Management LLC lifted its stake in shares of AtriCure by 3.3% in the fourth quarter. Hood River Capital Management LLC now owns 2,923,731 shares of the medical device company's stock valued at $89,349,000 after buying an additional 93,131 shares during the period. Champlain Investment Partners LLC lifted its position in shares of AtriCure by 4.3% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company's stock worth $78,253,000 after acquiring an additional 115,813 shares during the period. First Light Asset Management LLC lifted its position in shares of AtriCure by 5.6% in the 4th quarter. First Light Asset Management LLC now owns 1,969,221 shares of the medical device company's stock worth $60,179,000 after acquiring an additional 103,685 shares during the period. Wellington Management Group LLP lifted its position in AtriCure by 0.4% in the third quarter. Wellington Management Group LLP now owns 1,543,896 shares of the medical device company's stock worth $43,291,000 after purchasing an additional 6,045 shares during the period. Finally, State Street Corp lifted its position in AtriCure by 4.9% in the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock worth $37,710,000 after purchasing an additional 63,002 shares during the period. 99.11% of the stock is owned by institutional investors.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.